The impact of CXCL2 on ESCC immunotherapy was validated by ESCC mouse model.<h4>Results</h4>ScRNA-seq analysis showed that CXCL2 was predominantly expressed in macrophages within TME and significantly upregulated in immunotherapy-responsive ESCC patients. The gene discussed is CXCL2; the disease is esophageal squamous cell carcinoma.